Compare Neurocrine Biosciences Inc (NBIX) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Packaging Corporation of America — how do they compare? Neurocrine Biosciences Inc trades at $162.07 (market cap $16.76B), while Packaging Corporation of America trades at $257.2 (market cap $22.70B). The key difference: Packaging Corporation of America is the larger of the two by market cap, and Packaging Corporation of America pays a 2.36% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PKG | |
|---|---|---|
Market Cap | $16.76B | $22.70B |
Sector | Health | Technology |
52-Week High | $185.50 | $256.04 |
52-Week Low | $123.10 | $191.68 |
Enterprise Value | $16.78B | $26.51B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Packaging Corporation of America (PKG) trades at $256.04, up 1.3% on the day, with a bullish technical trend supported by moving averages and strong support at $252. The company reported Q2 2026 EPS of $2.35, beating estimates, driven by record corrugated shipments and contributions from the Greif acquisition, though net income margins face pressure from rising costs. A $1.50 dividend for H1-2026 reflects management's confidence, with a consensus price target of $269.33 suggesting modest upside.
Outlook: PKG benefits from robust demand and strategic acquisitions, but cost headwinds and a high P/E of 33.08 pose valuation risks. Analyst sentiment is mixed with 34.6% buy ratings, indicating cautious optimism amid margin compression and economic uncertainties. Key risks include freight and input cost inflation, competitive pricing pressure, and execution of integration synergies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
